Somatic PTEN mutation occurs in 4–8% of NSCLC [136,137], whereas PTEN overexpression inhibits lung cancer cell invasion and metastasis by inhibiting integrin αVβ6 signaling [138]. Here, PTEN is linked to lung carcinoma.